NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion

Journal of Molecular Cell Biology

Volumn 5, Issue 3, 2013, Pages 176-193

  Cattaruzza, Sabrina ^a   Nicolosi, Pier Andrea ^a   Braghetta, Paola ^b   Pazzaglia, Laura ^c   Benassi, Maria Serena ^c   Picci, Piero ^c   Lacrima, Katia ^d   Zanocco, Daniela ^a   Rizzo, Erika ^b   Stallcup, William B ^e   Colombatti, Alfonso ^a   Perris, Roberto ^a,b,c,d  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e BURNHAM INSTITUTE   (United States)

Author keywords

cell migration; collagen type VI; prognostic biomarker; proteoglycans; sarcoma; tumour stroma interaction

Indexed keywords

COLLAGEN TYPE 6; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEOCHONDROITIN SULFATE; VERY LATE ACTIVATION ANTIGEN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; BINDING SITE; CANCER GROWTH; CANCER PATIENT; CELL ADHESION; CELL ANCHORAGE; CELL INTERACTION; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; FIBROSARCOMA; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; LEIOMYOSARCOMA; LUNG PARENCHYMA; METASTASIS; MICROENVIRONMENT; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SARCOMA CELL; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TRANSPLANTATION; TUMOR ENGRAFTMENT; UPREGULATION;

CELL MIGRATION; COLLAGEN TYPE VI; PROGNOSTIC BIOMARKER; PROTEOGLYCANS; SARCOMA; TUMOUR-STROMA INTERACTION;

ADULT; AGED; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CHONDROITIN SULFATE PROTEOGLYCANS; COLLAGEN TYPE VI; HUMANS; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MIDDLE AGED; RNA INTERFERENCE; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE NEOPLASMS; TRANSFECTION; TUMOR MICROENVIRONMENT;

EID: 84877977594     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjt010     Document Type: Article

References (53)

1. Al-Mayhani, M.T., Grenfell, R., Narita, M., et al. (2011). NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature. Neuro. Oncol. 13, 830-845.
2. Benassi, M.S., Pazzaglia, L., Chiechi, A., et al. (2009). NG2 expression predicts the metastasis formation in soft-tissue sarcoma patients. J. Orthop. Res. 27, 135-140.
3. Burg, M.A., Tillet, E., Timpl, R., et al. (1996). Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules. J. Biol. Chem. 271, 26110-26116.
4. Burg, M.A., Nishiyama, A., and Stallcup, W.B. (1997). A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. Exp. Cell Res. 235, 254-264.
5. Burg, M.A., Grako, K.A., and Stallcup, W.B. (1998). Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells. J. Cell. Physiol. 177, 299-312.
6. Cattaruzza, S., Ozerdem, U., Denzel, M., et al. (2013). Multivalent proteoglycan modulation of FGF mitogenic responses in perivascular cells. Angiogenesis 16, 309-327.
7. Chatterjee, N., Stegmuller, J., Schatzle, P., et al. (2008). Interaction of syntenin-1 and the NG2 proteoglycan in migratory oligodendrocyte precursor cells. J. Biol. Chem. 283, 8310-8317.
8. Chekenya, M., Krakstad, C., Svendsen, A., et al. (2008). The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene 27, 5182-5194.
9. Daniels, K.J., Boldt, H.C., Martin, J.A., et al. (1996). Expression of type VI collagen in uveal melanoma: its role in pattern formation and tumor progression. Lab. Invest. 75, 55-66.
10. Eisenmann, K.M., McCarthy, J.B., Simpson, M.A., et al. (1999). Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat. Cell Biol. 1, 507-513.
11. Fang, X., Burg, M.A., Barritt, D., et al. (1999). Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. Mol. Biol. Cell 10, 3373-3387.
12. Fukushi, J., Makagiansar, I.T., and Stallcup, W.B. (2004). NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol. Biol. Cell 15, 3580-3590.
13. Gazziola, C., Cordani, N., Carta, S., et al. (2005). The relative endogenous expression levels of the IFNAR2 isoforms influence the cytostatic and pro-apoptotic effect of IFNalpha on pleomorphic sarcoma cells. Int. J. Oncol. 26, 129-140.
14. Han, J., Daniel, J.C., and Pappas, G.D. (1995). Expression of type VI collagen during glioblastoma cell invasion in brain tissue cultures. Cancer Lett. 88, 127-132.
15. Iida, J., Skubitz, A.P., Furcht, L.T., et al. (1992). Coordinate role for cell surface chondroitin sulfate proteoglycan and alpha 4 beta 1 integrin in mediating melanoma cell adhesion to fibronectin. J. Cell Biol. 118, 431-444.
16. Iida, J., Meijne, A.M., Spiro, R.C., et al. (1995). Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res. 55, 2177-2185.
17. Iida, J., Pei, D., Kang, T., et al. (2001). Melanoma chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human melanoma invasion into type I collagen. J. Biol. Chem. 276, 18786-18794.
18. Iyengar, P., Espina, V., Williams, T.W., et al. (2005). Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J. Clin. Invest. 115, 1163-1176.
19. Kageshita, T., Yamada, M., Arao, T., et al. (1992). Expression of high molecular weight-melanoma associated antigen (HMW-MAA) in primary ALM lesions is associated with a poor prognosis. Pigment Cell Res. Suppl 2, 132-135.
20. Lamande, S.R., Morgelin, M., Adams, N.E., et al. (2006). The C5 domain of the collagen VI alpha3(VI) chain is critical for extracellular microfibril formation and is present in the extracellular matrix of cultured cells. J. Biol. Chem. 281, 16607-16614.
21. Lin, X.H., Dahlin-Huppe, K., and Stallcup, W.B. (1996). Interaction of the NG2 proteoglycan with the actin cytoskeleton. J. Cell. Biochem. 63, 463-477.
22. Majumdar, M., Vuori, K., and Stallcup, W.B. (2003). Engagement of the NG2 proteoglycan triggers cell spreading via rac and p130cas. Cell. Signal. 15, 79-84.
23. Makagiansar, I.T., Williams, S., Dahlin-Huppe, K., et al. (2004). Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility. J. Biol. Chem. 279, 55262-55270.
24. Makagiansar, I.T., Williams, S., Mustelin, T., et al. (2007). Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. J. Cell Biol. 178, 155-165.
25. Midwood, K.S., and Salter, D.M. (2001). NG2/HMPG modulation of human articular chondrocyte adhesion to type VI collagen is lost in osteoarthritis. J. Pathol. 195, 631-635.
26. Mittelman, A., Chen, G.Z., Wong, G.Y., et al. (1995). Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin. Cancer Res. 1, 705-713.
27. Murray, J.L., Gillogly, M., Kawano, K., et al. (2004). Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res. 64, 5481-5488.
28. Nishiyama, A., and Stallcup, W.B. (1993). Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. Mol. Biol. Cell 4, 1097-1108.
29. Perris, R., Kuo, H.J., Glanville, R.W., et al. (1993). Neural crest cell interaction with type VI collagen is mediated by multiple cooperative binding sites within triple-helix and globular domains. Exp. Cell Res. 209, 103-117.
30. Petrovici, K., Graf, M., Hecht, K., et al. (2010). Use of NG2 (7.1) in AML as a tumor marker and its association with a poor prognosis. Cancer Genomics Proteomics 7, 173-180.
31. Rivera, Z., Ferrone, S., Wang, X., et al. (2012). CSPG4 as a target of antibodybased immunotherapy for malignant mesothelioma. Clin. Cancer Res. 18, 5352-63.
32. Ruhl, M., Johannsen, M., Atkinson, J., et al. (1999a). Soluble collagen VI induces tyrosine phosphorylation of paxillin and focal adhesion kinase and activates the MAP kinase erk2 in fibroblasts. Exp. Cell Res. 250, 548-557.
33. Ruhl, M., Sahin, E., Johannsen, M., et al. (1999b). Soluble collagen VI drives serum-starved fibroblasts through S phase and prevents apoptosis via down-regulation of Bax. J. Biol. Chem. 274, 34361-34368.
34. Sabatelli, P., Bonaldo, P., Lattanzi, G., et al. (2001). Collagen VI deficiency affects the organization of fibronectin in the extracellular matrix of cultured fibroblasts. Matrix Biol. 20, 475-486.
35. Schenker, T., and Trueb, B. (1998). Down-regulated proteins of mesenchymal tumor cells. Exp. Cell Res. 239, 161-168.
36. Sherman-Baust, C.A., Weeraratna, A.T., Rangel, L.B., et al. (2003). Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3, 377-386.
37. Smith, F.O., Rauch, C., Williams, D.E., et al. (1996). The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome band 11q23. Blood 87, 1123-1133.
38. Spessotto, P., Lacrima, K., Nicolosi, P.A., et al. (2009). Fluorescence-based assays for in vitro analysis of cell adhesion and migration. Methods Mol. Biol. 522, 221-250.
39. Stallcup, W.B., Dahlin, K., and Healy, P. (1990). Interaction of the NG2 chondroitin sulfate proteoglycan with type VI collagen. J. Cell Biol. 111, 3177-3188.
40. Svendsen, A., Verhoeff, J.J., Immervoll, H., et al. (2011). Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma. Acta Neuropathol. 122, 495-510.
41. Tigges, U., Hyer, E.G., Scharf, J., et al. (2008). FGF2-dependent neovascularization of subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages. Development 135, 523-532.
42. Tillet, E., Ruggiero, F., Nishiyama, A., et al. (1997). The membrane-spanning proteoglycan NG2 binds to collagens V and VI through the central nonglobular domain of its core protein. J. Biol. Chem. 272, 10769-10776.
43. Tillet, E., Gential, B., Garrone, R., et al. (2002). NG2 proteoglycan mediates beta1 integrin-independent cell adhesion and spreading on collagen VI. J. Cell. Biochem. 86, 726-736.
44. Virgintino, D., Girolamo, F., Errede, M., et al. (2007). An intimate interplay between precocious, migrating pericytes and endothelial cells governs human fetal brain angiogenesis. Angiogenesis 10, 35-45.
45. Virgintino, D., Perissinotto, D., Girolamo, F., et al. (2009). Differential distribution of aggrecan isoforms in perineuronal nets of the human cerebral cortex. J. Cell. Mol. Med. 13, 3151-3173.
46. Wagner, S., Krepler, C., Allwardt, D., et al. (2008). Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma- associated antigen mimotope vaccine. Clin. Cancer Res. 14, 8178-8183.
47. Wang, X., Osada, T., Wang, Y., et al. (2010a). CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J. Natl Cancer Inst. 102, 1496-1512.
48. Wang, X., Wang, Y., Yu, L., et al. (2010b). CSPG4 in cancer: multiple roles. Curr. Mol. Med. 10, 419-429.
49. Wang, J., Svendsen, A., Kmiecik, J., et al. (2011a). Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma. PLoS One 6, e23062.
50. Wang, X., Katayama, A., Wang, Y., et al. (2011b). Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res. 71, 7410-7422.
51. Weiger, M.C., Wang, C.C., Krajcovic, M., et al. (2009). Spontaneous phosphoinositide 3-kinase signaling dynamics drive spreading and random migration of fibroblasts. J. Cell Sci. 122, 313-323.
52. Yang, J., Price, M.A., Neudauer, C.L., et al. (2004). Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J. Cell Biol. 165, 881-891.
53. You, W.K., Bonaldo, P., and Stallcup, W.B. (2012). Collagen VI ablation retards brain tumor progression due to deficits in assembly of the vascular basal lamina. Am. J. Pathol. 180, 1145-1158.